Please assess the completion status of the following clinical trial:

Trial Title: Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed neuroblastoma or ganglioneuroblastoma meeting 1 of the following staging criteria:~  * Newly diagnosed disease, at least 1 year of age, and meets criteria for 1 of the following:~    * International Neuroblastoma Staging System (INSS) stage 2a/2b with MYCN amplification (greater than 10) AND unfavorable pathology~   * INSS stage 3 with MYCN amplification OR unfavorable pathology~ * Newly diagnosed INSS stage 4 disease meeting criteria for 1 of the following:~    * Over 18 months of age~   * Age 12 to 18 months with any unfavorable biologic feature (MYCN amplification, unfavorable pathology, and/or DNA index=1) or any biologic feature that is indeterminant, unsatisfactory, or unknown~      * No INSS stage 4 disease and age 12 to 18 months with all 3 favorable biologic features (i.e., nonamplified MYCN, favorable pathology, and DNA index greater than 1)~ * Newly diagnosed INSS stage 3, 4, or 4S disease AND under 1 year of age with MYCN amplification~ * At least 1 year of age and initially diagnosed with INSS stage 1, 2, or 4S disease that progressed to stage 4 without interval chemotherapy~    * Must have been enrolled on COG-ANBL00B1 at initial diagnosis~PATIENT CHARACTERISTICS:~Age~* 30 and under at initial diagnosis~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count at least 1,000/mm\^3\*~* Platelet count at least 100,000/mm\^3\* (transfusion independent)~* Hemoglobin at least 10.0 g/dL\* (red blood cell transfusions allowed) NOTE: \*Granulocytopenia, anemia, and/or thrombocytopenia allowed for patients with tumor metastatic to the bone marrow~Hepatic~* Bilirubin no greater than 1.5 mg/dL~* ALT less than 300 IU/L~Renal~* Creatinine no greater than 1.5 mg/dL~* Creatinine clearance or radioisotope glomerular filtration rate at least 60 mL/min~Cardiovascular~* ECG normal~* Shortening fraction at least 27% by echocardiogram OR~* Ejection fraction at least 50% by MUGA~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* HIV negative~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* See Disease Characteristics~* No more than 1 prior chemotherapy course on the low- or intermediate-risk neuroblastoma studies (COG-P9641, COG-A3961) prior to determination of MYCN amplification and Shimada histology~Endocrine therapy~* Not specified~Radiotherapy~* Prior localized emergency radiotherapy to sites of life-threatening or function-threatening disease allowed~Surgery~* Not specified~Other~* No other prior systemic therapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- All patients (Type: EXPERIMENTAL): Induction Cycles 1 and 2 (CT) (21 days each), Cyclophosphamide (Days 1 thru 5) weight based dosage (\> 12 kg 400 mg/m2/day, \< 12 kg 13.3 mg/kg/day, \< 2 years old N/A. Topotecan (Days 1 thru 5) weight based dosage (\> 12 kg 1.2 mg/m2/day, \< 12 kg 0.04 mg/kg/day, \< 2 years old 0.04 mg/kg/day). Filgrastim (Days 6 →) weight based dosage (\> 12 kg 5 micrograms/kg, \< 12 kg 5 micrograms /kg, \< 2 years old 5 micrograms /kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).